 NEW YORK and LONDON, Sept. 10, 2021 GLOBE NEWSWIRE -- Akari Therapeutics, Plc Nasdaq: AKTX, a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement C5 andor leukotriene LTB4 systems are implicated, today announced that Miles Nunn, Ph.D., Chief Scientific Officer of Akari Therapeutics, and Sanjeev Khindri, M.D., Medical Director of Akari Therapeutics, will present a poster outlining the design of the Companys Phase III planned pivotal study of nomacopan in patients with moderate to severe bullous pemphigoid BP at the 2021 International Pemphigus Pemphigoid Foundation IPPF Scientific Symposium. 